{"id":464433,"date":"2010-03-24T00:01:37","date_gmt":"2010-03-24T04:01:37","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=69929"},"modified":"2010-03-24T00:01:37","modified_gmt":"2010-03-24T04:01:37","slug":"novell-turns-down-buyout-offer-alnylam-pulls-in-20m-from-takeda-16m-stock-deal-goes-to-rxi-more-boston-area-deals-news","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/464433","title":{"rendered":"Novell Turns Down Buyout Offer, Alnylam Pulls In $20M from Takeda, $16M Stock Deal Goes to RXi, & More Boston-Area Deals News"},"content":{"rendered":"\n
Roundup<\/a>, deals<\/a>, funding<\/a><\/div>\n

\t\tErin Kutz wrote:<\/strong><\/p>\n

It was a lighter deals week for us, but we still saw headlines of funding rounds, partnerships, and stock offerings for companies in Internet, software, and life sciences.<\/p>\n

—Boston-based Swaptree, an online marketplace for trading books, CDs, DVDs, and video games, grabbed $4.8 million of a planned $6 million offering based in equity, options, and warrants<\/a>. The company didn’t reveal the investors in the financing.<\/p>\n

—Novell (NASDAQ:NOVL<\/a>), a network software maker, rejected a $2 billion buyout offer from private equity firm Elliott Associates<\/a>. The Waltham, MA-based company’s board said the $5.75-per-share bid undervalued Novell’s growth prospects, and said that it would pursue other possible strategies for enhancing shareholder value, such as cash dividends or stock repurchases.<\/p>\n

—Alnylam Pharmaceuticals (NASDAQ:ALNY<\/a>), the Cambridge, MA-based drugmaker, received a $20 million payment from Takeda Pharmaceuticals, as part of a partnership deal established between the two companies<\/a> in 2008 that could ultimately be worth more than $1 billion. This week’s payment was related to Alnylam sharing its RNA interference material and information, but the company stands to pull in more milestone payments and royalties if Japan-based Takeda uses the technology to create RNAi products.<\/p>\n

—Another developer of RNA interference-based treatments, RXi Pharmaceuticals (NASDAQ: RXII<\/a>) of Worcester, MA, announced it had raised $16.2 million through a stock offering<\/a>. Investors agreed to pay $6 per share for 2.7 million shares, a 26 percent discount over the stock’s $8.11 closing share price on Monday. They’ll also purchase warrants for another 540,000 shares.<\/p>\n

—SmartCells, a developer of a once-a-day, self-regulating, injectable treatment for diabetes, has pulled in $1.75 million<\/a> in an equity-based offering, a regulatory filing revealed. The Beverly, MA-based company did not indicate what round of financing the planned $4 million round represents.<\/p>\n

Comments<\/a> | Reprints<\/a> | Share:  
\n\"Retweet\"\/<\/a>
\n \"Facebook\"\/<\/a>
\n \"Email\"\/<\/a>
\n \"Share\"\/<\/a>\n<\/div>\n

\t \t\t

\n

\n\"\"<\/a>
\n<\/p>\n

<\/img><\/a>
\n<\/img><\/a><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Roundup, deals, funding Erin Kutz wrote: It was a lighter deals week for us, but we still saw headlines of funding rounds, partnerships, and stock offerings for companies in Internet, software, and life sciences. —Boston-based Swaptree, an online marketplace for trading books, CDs, DVDs, and video games, grabbed $4.8 million of a planned $6 million […]<\/p>\n","protected":false},"author":1661,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,7,10],"tags":[],"class_list":["post-464433","post","type-post","status-publish","format-standard","hentry","category-internet","category-news","category-software"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/464433","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1661"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=464433"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/464433\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=464433"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=464433"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=464433"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}